What is Accuracap's investment strategy?
Accuracap is covered in Rupeia's Category III AIF research universe. The current public record describes the strategy as Long-only; quantitative and systematic, with a focus of Small and micro cap, multicap, flexicap, Indian listed equity. The profile should be read with the linked source trail and Category III AIF context.
What performance evidence is available for Accuracap?
Vectra Fund: 3M 3.00%, 6M 27.30%, 1Y 18.20% and since inception 19.30%. AlphaGen Next Fund: 3M -3.30%, 6M 9.00%, 1Y 0.50%, 3Y 5.10%, 5Y 4.50% and since inception 8.80%. Figures are as of 30 September 2026, after expenses and tax.
What is known about Accuracap's performance or track record?
Two named AIFs disclose at least four return windows each on the same date and state that results are after expenses and tax. Confirm the named scheme, measurement date, return basis and benchmark in current fund reporting.
What are Accuracap's fund size, fees and minimum investment?
Public fund size: not publicly disclosed. Public terms or access information: Reported minimum investment ₹1 crore; current fees, lock-in and redemption terms require the scheme documents. Current fees, minimum commitment and availability must be confirmed for the exact named vehicle in its fund documents.
Who is on Accuracap's investment team?
The current source record names Dr. Naresh Chand Gupta (Founder, CEO and Lead Fund Manager); Raman Nagpal (Co-Manager, Vectra Fund). Verify current roles, departures, attribution and key-person provisions before relying on the team history for a new commitment.
What risks should be reviewed before investing with Accuracap?
Review strategy drift, benchmark mismatch, leverage, derivatives, concentration, drawdown, valuation basis and redemption liquidity. The current open diligence point is: Compare the post-tax fund figures with pre-tax benchmarks and review model governance, override authority, turnover, capacity and exit rules in the current PPM.
What is the latest public update on Accuracap?
2026-09-30: The manager reported Vectra and AlphaGen Next performance through 30 September 2026 with an after-expenses-and-tax basis.